
Sten Sörensen, Cereno Scientific CEO
Cereno Scientific details mid-stage results for pulmonary arterial hypertension drug
Cereno Scientific’s HDAC inhibitor hit the primary endpoint of safety and tolerability in a Phase 2a trial in patients with pulmonary arterial hypertension, sending its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.